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AbstrAct
Aims: Overlap syndromes constitute a significant proportion of autoimmune liver disease. Our aim was to describe our cohort 
and evaluate practical methods of correctly diagnosing autoimmune hepatitis / primary sclerosing cholangitis overlap syndrome 
as early as possible clinically.
Methods: 118 autoimmune hepatitis patients were screened for cholestatic liver function tests. 24 patients with cholestatic liver 
function tests were investigated for possible primary sclerosing cholangitis by clinicopathological review and magnetic resonance 
cholangiography. Retrospectively, potential predictors of autoimmune hepatitis / primary sclerosing cholangitis overlap syndrome 
were compared with a control group. 
Results: Overlap syndrome was diagnosed in twelve (50%) of 24 autoimmune hepatitis patients with recent cholestasis. The 
cholestatic group had a lower AST (p=0.012) and International Autoimmune Hepatitis Group (IAHG) score (p=0.102), and 
higher IgM (p=0.002) at disease presentation. More patients in the cholestatic group developed ulcerative colitis (p=0.138).
Conclusions: Identifying AIH / PSC overlap syndrome at diagnosis is often difficult. Certain clinical and biochemical features 
should alert the clinician. All patients with AIH, and biochemical cholestasis should be investigated with MRC.
Keywords: Autoimmune hepatitis; overlap; primary sclerosing cholangitis. 
introduction
Autoimmune liver disease largely comprises autoimmune 
hepatitis (AIH), primary sclerosing cholangitis (PSC) 
and primary biliary cirrhosis (PBC). The understanding, 
definition, and treatment of autoimmune liver disease has 
changed since first described during the 1950s. Narrower 
case definitions and improved treatment have resulted from 
increased clinical awareness, enhanced by biochemical, 
serological, histological, and radiological techniques1,2.
Since the 1980s, “overlap syndromes” (OLS) of autoimmune 
liver diseases have been described. OLS indicates a variant 
form of autoimmune liver disease with characteristics of 
AIH and PSC or AIH and PBC. The patient may present with 
features suggesting OLS, or develop them during the course 
of an initially “pure” autoimmune liver disease. Accurate 
categorisation  and characterisation of overlap syndromes 
requires a high index of suspicion during evaluation of 
clinical, biochemical, immunological, histological and 
radiological features. Patients with OLS have a different 
disease course and require specific therapy. Compared 
to 20 years ago, overlap syndromes are more frequently 
diagnosed  3, and have been the subject of several recent 
clinical reviews2,4,5. Recognising OLS early offers optimum 
disease management to individual patients. Clearly defining 
OLS, rather than only utilising pure diagnostic categories of © The Ulster Medical Society, 2011.
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autoimmune liver disease, offers an opportunity to assess 
pathogenic mechanisms and develop treatment strategies.
A useful tool in the study of autoimmune liver disease has 
been the International Autoimmune Hepatitis Group (IAHG) 
‘score’ for AIH. This scoring for AIH was introduced in 
1992 6 and subsequently revised in 1999 7. The IAHG score 
has been validated by prospective review 8, and found to 
have high sensitivity (98%) and moderate specificity (60-
80%) for a diagnosis of AIH 9. These IAHG criteria have not 
been designed or validated for OLS. However the criteria 
have enabled clinicians to compare cohorts of patients, and 
objectively study other liver diseases for features of AIH.
In cohorts of patients with AIH, the incidence of AIH / PSC 
OLS is described between 7% 10 and 10% 11. In cohorts of 
patients with PSC, the incidence of AIH / PSC OLS has been 
described as 7% 12, 8% 13, 17% 14, and 54% 15. The variation 
in prevalence rates may be attributed to different patient 
inclusion criteria and methods of screening for disease. Study 
analysis reveals that some retrospective studies suffer from 
incomplete data, poorly defined patient groups, and variation 
of the criteria used for diagnosis.  
The clinical importance of early diagnosis, the improved 
quality and availability of Magnetic Resonance 
Cholangiography (MRC), and the variation of disease 
prevalence between previously published cohorts suggest a 
need for further investigation,. This study seeks to define the 
epidemiology of AIH / PSC OLS retrospectively in a cohort 
of patients with AIH, and to determine which investigations 
should be rationally employed to improve diagnosis.
MetHods
Patient selection
118 patients attending the Liver Clinic in a large, teaching 
hospital with a diagnosis of autoimmune hepatitis, were 
included in the study. The initial diagnosis was based on 
clinical presentation, biochemistry, immunoglobulins 
and autoantibody profiles and, where a liver biopsy was 
performed, histology. Follow-up since initial diagnosis ranged 
from 2 to 26 years [median 12 years].
Study design and patient data
Those patients presumed to be at greatest risk of AIH / PSC 
OLS on the basis of biochemical liver function test (LFT) 
pattern were selected from the cohort. LFTs from the last 
three clinic visits were reviewed to identify all patients with 
cholestatic LFTs (defined as above normal ranges: GGT> 
58 U/l and ALP >120 U/l). Our choice of ‘cut-off’ for 
“persistently elevated ALP or GGT” is based on previously 
described AIH cohorts3.  This “cholestatic LFT group” 
comprised 24 patients, who subsequently underwent biliary 
tract evaluation by  MRC, if not already performed. A 
radiologist (P.E.) reviewed each MRC specifically for features 
of PSC. Results were graded as “consistent with PSC”,   
“suspicious of PSC”, or “no evidence of PSC”.
In an effort to identify distinguishing features possibly 
predicting OLS at the time of original diagnosis of AIH, we 
retrospectively compared the baseline characteristics of this 
cholestatic group with control patients. 25 control patients 
were randomly sampled from the remaining AIH cohort and 
matched by gender and age (±5 years). This group did not 
undergo evaluation by MRC. 
For each patient in the study and control groups (total 
n=49), the IAHG score was calculated for the time of initial 
presentation. According to IAHG criteria6,7, a pre-treatment 
aggregate score of >15 is ‘definite AIH’, and 10 – 15 is 
‘probable AIH’. Any diagnosis of ulcerative colitis was 
recorded, given the association with PSC.
Where available, slides from a liver biopsy performed at initial 
presentation i.e. before treatment, were blindly reviewed by 
two liver pathologists independently (M.L., M.G.) for well-
described features of hepatitis or biliary disease modified 
from previous studies16,17. Depending on the variable in 
question, either a two-tier (0 or 1) or three-tier (0, 1 or 2) 
scoring system was employed. Necroinflammatory activity 
and fibrosis were scored according to the familiar modified 
Knodell hepatic activity index (HAI) system on scales of 
0-4 or 0-6 18. For any features included in the histological 
component of the IAHG scoring system, the definitions used 
by the IAHG were followed where possible. Specifically, these 
describe “biliary changes” as “bile duct changes typical of 
PBC/PSC and/or a substantial periportal ductular reaction 
with copper/copper-associated protein accumulation”. 
Figure 1:Time to diagnosis of AIH / PSC 'overlap' (n=12) out of the total population with initial diagnosis of 
'pure' AIH (n=118). Range of time to follow up: 2 – 26 years
Table 1: Clinical and laboratory characteristics at clinical presentation of AIH patients who developed 
cholestatic LFTs and a control AIH group. 
Characteristic





Female (%) 14 (58) 15 (60) 1.000
Age at presentation 40.2 (±15.6) 43.4 (±15.7) 0.503
AST (u/L) 271 (±338) 722 (±692) 0.012
ALP (u/L) 463 (±528) 263 (±180) 0.084
IgG (g/dL) 21.0 (±12.0) 20.8 (±11.5) 0.990
IgM (g/dL) 2.47 (±1.44) 1.42 (±0.78) 0.002
ANA or SMA (titre ≥1:40) 15  12  0.365
AMA (titre ≥1:40)  2  0  0.488
Alcohol intake <25g/day  23  22  0.600
Other autoimmune disease1  4  0.349
Diabetes Mellitus  4  5  1.000
Ulcerative Colitis  6  2  0.138
IAHG score 8.3 (±6.0) 12.6 (±4.9) 0.102
Values are mean (±standard deviation), or categorical frequency
Fig 1. Time to diagnosis of  AIH / PSC ‘overlap’ syndrome in 
patients with AIH. n-118
Table 1:
Clinical and laboratory characteristics at clinical 
presentation of AIH patients who developed cholestatic 
LFTs and a control AIH group© The Ulster Medical Society, 2011.
Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis  
overlap syndrome in adults with autoimmune hepatitis 17
www.ums.ac.uk
Statistical analysis
The Mann-Whitney test (for continuous, non-parametric 
data) was used to compare the cohort with the control group. 
The two-tailed Fisher’s exact test (employed because of the 
small sample size) was used to compare categorical variables. 
The Gamma test for concordance or discordance of ordinal 
variables was used to compare each patient group for degree 
of histological features. p-values <0.05 were considered 
significant. SPSS (Chicago, IL. USA. Edition 15.0, 2007) was 
used for statistical analysis.
resuLts
The clinical and laboratory characteristics from the time of 
diagnosis of the cholestatic group of AIH patients (n=24) 
and the matched control AIH group (n=25) are summarised 
in Table 1. The cholestatic group had a lower AST (p=0.012), 
higher IgM (p=0.002), and lower IAHG score (p=0.102) 
at presentation compared to the control group. The other 
parameters recorded were similar for both groups.
Only 10 of the 24 patients with cholestatic LFTs (including 
four of the 12 overlap cases), and 15 of the 25 patients in the 
control group, had an initial liver biopsy which was available 
for review. Therefore statistical evaluation of histology data 
was limited. Of the histological features assessed (Table 2), 
ductopenia, substantial periportal ductular reaction, copper-
associated protein deposition, and overall ‘biliary changes’, 
as defined by IAHG criteria, occurred more frequently in the 
cholestatic group and hepatitic features were more prominent 
in the control AIH group, but none of the changes reached   
statistical significance.
In our cohort, 12 (50%) of AIH patients with cholestatic LFTs 
had features of PSC on MRC. At the time of initiation of this 
study, eight cases of AIH had already been reclassified as AIH 
/ PSC overlap syndrome. During the course of this study, four 
more patients with cholestatic LFTs were demonstrated to 
have cholangiographic features consistent with or suspicious 
of PSC.
Comparison of the AIH / PSC OLS group (defined by 
abnormal MRC), the cholestatic LFT group (with normal 
MRC), and the control AIH group, showed a similar duration 
of clinical follow up (mean 11.2 years, range 2-28 years). 
Rates of clinical remission, relapse, liver failure requiring 
transplantation, or death, were similar between each of these 
three groups.
discussion
This study showed that, of 24 patients who were identified 
from a cohort of 118 AIH patients by the development of 
cholestatic LFTs, one half (12/24) had features of PSC on 
MRC evaluation, indicating a diagnosis of AIH / PSC OLS. 
A retrospective comparison of this cholestatic group with a 
control population at the time of presentation, was performed 
in an attempt to identify important early predictive features 
for developing OLS. At time of original diagnosis of AIH, 
patients in the cholestatic group had lower transaminases, 
higher serum IgM levels and a greater incidence of ulcerative 
colitis. IAHG scores were lower than the control group. In our 
cohort, no other clinical or pathological differences between 
the two groups were statistically significant.
Many groups have studied patients with autoimmune liver 
disease. Abdamlian et al.11  prospectively studied 79 patients 
with a clinical diagnosis of AIH. They found that 10% had 
definite or probable PSC on MRC. Predictors of PSC were 
younger age at diagnosis, elevated alkaline phophatase at 
diagnosis, elevated bilirubin at time of MRC, and greater 
lobular activity on initial liver biopsy. Gheorghe et al.10 
studied 82 patients with AIH. Only eight of this group 
underwent ERCP (based on a cholestatic biochemical or 
histological profile), of which seven were positive for features 
of PSC. Therefore at least 7% of their AIH cohort had features 
of AIH / PSC OLS. Our finding that at least 12 (10%) of 
118 AIH patients developed AIH / PSC OLS is consistent 
with these studies. The most comprehensive descriptive 
epidemiology of autoimmune liver disease prevalence and 
categorisation comes from Czaja et al.15, who retrospectively 
reviewed 225 patients with any autoimmune liver disease. Of 
the 225 patients, 18% were reclassified as having OLS. 14 of 
26 patients with PSC (54%) were found to have features of 
AIH and PSC. 
Four large studies have reviewed patients with 
cholangiographically-proven PSC for features of AIH 
(assessed by IAHG criteria7). Kaya et al.12 (n=211) reported 
1.4% of PSC cases had ‘definite’ AIH and 6% had ‘probable’ 
AIH. Floriani et al.14 (n=41) found 17% with AIH, van Burren 
et al.13(n=113) found 8% with ‘definite’ AIH, and Boberg et 
al.4 (n=114) found 2% with ‘definite’ and 33% with ‘probable’ 
AIH.
The pathogenesis, time of disease onset, and sequence of 
progression of AIH / PSC OLS is poorly understood5,19,20. 
Retrospective analysis of the initial diagnosis is usually 
impossible because most patients do not have both 
cholangiography and liver biopsy performed at time of 
diagnosis of AIH. McNair et al.21 presented five cases of 
AIH / PSC OLS. Two had ‘pure’ AIH at diagnosis, which 
transformed into AIH / PSC OLS subsequently. Three 
had concurrent features of AIH and PSC at presentation. 
Abdo et al.22 reviewed 91 patients with AIH. Six patients 
(7%) subsequently developed cholangiographically-proven 
PSC. This included three patients with a previously normal 
cholangiogram, performed after the initial diagnosis of AIH. 
Gregorio et al.23 prospectively studied children attending 
King’s College Hospital liver clinic (London, UK) with 
Table 2: Pathological features of pre-treatment liver biopsy at diagnosis of AIH in patients who subsequently 
developed cholestatic LFTs compared to AIH control group. 





Granulomatous cholangitis (%) 1 (10) 0 (0) 0.400
Lymphocytic cholangitis (%) 2 (20) 1 (7) 0.426
Neutrophilic cholangitis (%) 0 (0) 2 (13) 0.500
Concentric periductal fibrosis (%) 0 (0) 1 (7) 1.000
Ductopenia (%) 3 (30) 1 (7) 0.267
Substantial periportal ductular reaction (%)  6 (60) 6 (40) 0.124
Copper-associated protein deposits (%) 5 (50) 2 (13) 0.132
Cholate stasis (%) 2 (20) 1 (7) 0.543
Canalicular cholestasis (%) 1 (10) 5 (33) 0.289
Biliary changes (IAHG defn) (%) 4 (40) 2 (13) 0.175
Predominant lymphoplasmacytic infiltrate (%)6 (60) 9 (60) 1.000
Liver cell rosetting (%) 2 (20) 5 (33) 0.659
Severe interface hepatitis (%) 2 (20) 6 (40) 0.232
Confluent necrosis (%) 2 (20) 7 (47) 0.439
Moderate/severe spotty necrosis (%) 3 (30) 8 (53) 0.626
Marked portal inflammation (%) 1 (10) 4 (27) 0.453
Modified HAI fibrosis staging score (mean?) 2.5 (±2.2) 1.3 (±1.3) 0.221
Values are mean (±standard deviation), or categorical frequency
Table 2:
Pathological features of pre-treatment liver biopsy at 
diagnosis of AIH in patients who subsequently developed 
cholestatic LFTs compared to AIH control group© The Ulster Medical Society, 2011.
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a diagnosis of AIH (n=28) or PSC (n=27). All patients 
underwent biopsy and cholangiography at presentation. Of 
the 27 patients with PSC, 14 (52%) had ‘definite’ and 13 
(48%) ‘probable’ AIH by IAHG scores. One patient with 
‘pure’ AIH and normal cholangiography at presentation, 
subsequently developed cholangiographically-proven PSC. 
As discussed by these and other authors, it appears that some 
cases of ‘pure’ AIH, with no features to indicate AIH / PSC 
OLS at diagnosis originally, subsequently can transform into 
AIH / PSC OLS21,22.
The main weaknesses of this study are the small number 
of patients and incomplete data. Clinical notes for baseline 
data at diagnosis were not always available due to the long 
duration of follow-up. Many cases did not have a liver biopsy 
performed and some liver biopsies were unavailable or 
uninterpretable. MRC scanning is clearly preferable to ERCP 
from a patient perspective, but may cause claustrophobia, 
which prevented MRC in one case. MRC has a sensitivity of 
82 to 91% and specificity of 85 to 98% 24,25, when compared 
to the ‘gold standard’ ERCP for the diagnosis of PSC. The 
sensitivity of MRC has improved due to better availability and 
quality of MR scanning. ‘Small duct’ PSC (biochemical and 
histological features of PSC, but normal cholangiography) 
will not necessarily have been identified by our investigations. 
Angulo et al.26 identified 18 patients (5.8%) from their PSC 
cohort (n=309), with ‘small duct’ PSC. Only 25 AIH patients, 
out of our cohort of 118, underwent cholangiography. 
Therefore, the prevalence of AIH / PSC OLS may be even 
greater in our cohort.
This is the first study to examine whether an earlier diagnosis 
of AIH/PSC OLS could be made in patients with an initial 
clinical diagnosis of AIH. Our study reiterates the finding 
of other groups: a significant minority of patients diagnosed 
with AIH will eventually turn out to have AIH / PSC OLS. 
There are no clinical, biochemical, serological or histological 
findings which strongly predict this development. Therefore, 
we recommend that MRC should be performed in every 
case of AIH where there is an elevation of ALP and GGT, 
following a poor transaminase response to corticosteroids. In 
the event of a normal MRC, liver biopsy should be considered 
to look for small duct disease. The frequency with which 
MRC should be performed and whether MRC would reveal 
cases of AIH/PSC OLS in AIH patients with normal ALP and 
GGT remain to be determined.
The authors have no conflict of interest.
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